CBL-514

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Subcutaneous Fat

Conditions

Subcutaneous Fat

Trial Timeline

Feb 11, 2022 → Jun 9, 2022

NCT ID

NCT05234736

About CBL-514

CBL-514 is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT05234736. Target conditions include Subcutaneous Fat.

What happened to similar drugs?

0 of 3 similar drugs in Subcutaneous Fat were approved

Approved (0) Terminated (0) Active (3)

🔄TR-701 FA + LinezolidMerckPhase 3

🔄CBL-514 InjectionCaliway BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05234736	Phase 2	Completed	Feb 11, 2022	Jun 9, 2022	Subcutaneous Fat
NCT04575467	Phase 2	Completed	Dec 9, 2020	Dec 8, 2021	Subcutaneous Fat
NCT04698642	Phase 2	Completed	Feb 3, 2020	Nov 12, 2020	Subcutaneous Fat

Competing Products

9 competing products in Subcutaneous Fat

See all competitors

Product	Company	Stage	Hype Score
TR-701 FA + Linezolid	Merck	Phase 3	40
TR-701 FA + Linezolid	Merck	Phase 3	40
CBL-514	Caliway Biopharmaceuticals	Phase 2	35
CBL-514 Injection	Caliway Biopharmaceuticals	Phase 2	35
CBL-514, placebo + CBL-514, placebo + CBL-514	Caliway Biopharmaceuticals	Phase 1	29
CBL-514 Injection	Caliway Biopharmaceuticals	Phase 2	35
CBL-514 Injection	Caliway Biopharmaceuticals	Phase 3	47
CBL-514	Caliway Biopharmaceuticals	Phase 2	35
CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride	Caliway Biopharmaceuticals	Phase 2	35